Joseph Benesch sold $7,084 of DERM
CFO at Journey Medical Corp. 1,365 shares at an average of $5.19, traded Feb 21, 2025, filed Feb 24, 2025.
Score components
- +22RoleCFO
- 0Trade size$7k at market
- 0Share of holdings soldSold 2.9% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-016490, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | SOpen-market sale Common Stock, $0.0001 par value | -1,365 | $5.19 | $7,084 | 45,966 | Feb 24, 2025 |
Related signals
Other insiders at Journey Medical Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | Journey Medical Corp | Ramsey Alloush COO | $20k 2,857 shares | -1% | |
| 37Weak | Journey Medical Corp | Joseph Benesch CFO | $16k 2,409 shares | -1% | |
| 46Moderate | Journey Medical Corp | Claude Maraoui President & CEO | $33k 4,834 shares | -0% | |
| 38Weak | DERMsell Journey Medical Corp | Claude Maraoui President & CEO | $247k 49,271 shares | -2% | |
| 45Moderate | Journey Medical Corp | Claude Maraoui President & CEO | $203k 40,456 shares | -2% | |
| 48Moderate | Journey Medical Corp | Claude Maraoui President & CEO | $361k 70,556 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.